An 80‐year‐old male, with relapsed mantle cell lymphoma was treated on a trial with the combination of the bruton tyrosine kinase (BTK) inhibitor, ibrutinib, and BH3‐mimetic, venetoclax, and achieved complete remission by both Computerized Tomography‐Positron Emission Tomography (CT‐PET) and molecular assessment. This evidence concerns the gene BTK and mantle cell lymphoma.